Telbivudine treatment of hepatitis B virus-infected pregnant women at different gestational stages for the prevention of mother-to-child transmission: Outcomes of telbivudine treatment during pregnancy

This prospective study evaluated the viability of telbivudine for blocking mother-to-child transmission (MTCT) of hepatitis B virus (HBV) infection. Pregnant women positive for the hepatitis B surface antigen began telbivudine treatment before 14 weeks of gestation (i.e., early), between 14 and 28 w...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Zhangmin, Yin, Yuzhu, Zhou, Jin, Wu, Lingling, Xu, Chengfang, Hou, Hongying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
5600
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059039/
https://www.ncbi.nlm.nih.gov/pubmed/27749537
http://dx.doi.org/10.1097/MD.0000000000004847

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059039/
https://www.ncbi.nlm.nih.gov/pubmed/27749537
http://dx.doi.org/10.1097/MD.0000000000004847

Ejemplares similares